QR kód

Frailty, Pitavastatin, and Major Adverse Cardiovascular Events Among People With HIV

Background: People with HIV (PWH) are at increased risk for atherosclerotic cardiovascular diseases (ASCVDs) and geriatric syndromes, including frailty. REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) demonstrated a 36% reduction in major adverse cardiovascular events (MACE) with pitav...

Celý popis

Uloženo v:
Hlavní autoři: Kristine M. Erlandson, MD, MS, Ariela R. Orkaby, MD, Triin Umbleja, MSc, Heather J. Ribaudo, PhD, Todd T. Brown, MD, PhD, Markella V. Zanni, MD, Marissa R. Diggs, AB, Sarah M. Chu, MSN, Kathleen V. Fitch, MSN, Carl J. Fichtenbaum, MD, Carlos Malvestutto, MD, MPH, Judith A. Aberg, MD, Gerald S. Bloomfield, MD, MPH, Judith S. Currier, MD, Karen T. Tashima, MD, Marcus Vinícius Guimarães de Lacerda, MD, PhD, Sonya L. Heath, MD, Michael T. Lu, MD, MPH, Alan Landay, PhD, George A. Kuchel, MD, Pamela S. Douglas, MD, Steven K. Grinspoon, MD
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2025-09-01
Edice:JACC: Advances
Témata:
frailty
HIV
major adverse cardiovascular event
statin
On-line přístup:http://www.sciencedirect.com/science/article/pii/S2772963X25005022
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky